CompletedPhase 4

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

United States221 participantsStarted 2004-12-02

Plain-language summary

This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.

Who can participate

Age range45 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women 45-65 years * naturally or surgically postmenopausal * experiencing hot flushes Exclusion Criteria: * hypersensitivity to estrogen replacement therapy * pregnancy or lactating * abnormal PAP smear * history/suspected cervical, uterine, adrenal, pituitary, breast or ovarian malignancy

Trial details

NCT IDNCT00160173

SponsorASCEND Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-09-06

View on ClinicalTrials.gov More Postmenopausal Symptoms trials